High ferritin in homozygous and heterozygous β-thalassemia tends to decrease oxidative stress levels
Article Sidebar
Main Article Content
Abstract
Background
Ineffective erythropoiesis and multiple blood transfusions may cause iron overload, leading to high level of ferritin in β-thalassemia patients. Iron has the ability to catalyze the production of reactive oxygen species (ROS), which can be prevented by an adequate activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx). The aim of this study was to explore the association between high ferritin levels and oxidative stress among β-thalassemia patients by measuring SOD and GPx levels.
Methods
This was a cross sectional study among β-thalassemia major patients. Ferritin, SOD, and GPx were measured and compared between β-thalassemia patients with homozygous IVS1nt5 and heterozygous IVS1nt5/HbE mutations, which were the most prevalent mutations found in our previous study. The Spearman correlation test was used to analyze the data.
Results
The ferritin levels in all β-thalassemia major patients were very high (range: 791-12,340 µg/L). However, no significant differences were observed (p=0.318) between homozygous IVS1nt5 (n=45) compared to heterozygous IVS1nt5/HbE (n=13). The oxidative stress markers SOD and GPx were not significantly different between homozygous IVS1nt5 and heterozygous IVS1nt5/HbE (p=0.450 and p=0.323, respectively). The correlations between ferritin and SOD and GPx oxidative stress levels were not significant in both homozygous IVS1nt5 and heterozygous IVS1nt5/HbE mutations.
Conclusion
High ferritin levels in β-thalassemia patients tend to decrease the GPx level in all thalassemia patients and SOD level in half of the patients, indicating that GPx and SOD may play a role in the occurrence of oxidative stress among thalassemia patients. The mechanism of oxidative stress in thalassemia needs to be further explored.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Kumar R, Sagar C, Sharma D, et al. β-globin genes: mutation hot-spots in the global thalassemia belt. Hemoglobin 2015;39:1-8. doi: 10.3109/03630269. 2014.985831.
Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of beta-thalassemias and hemoglobin E disorders. Expert Rev Hematol 2010;3:103-17. doi: 10.1586/EHM. 09.74.
Departemen Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. Riset Kesehatan Dasar (RISKESDAS) 2007, Laporan nasional 2007. Jakarta: Departemen Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia; 2008.
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5. doi: 10.1186/1750-1172-5-11.
Kohgo Y, Ikuta K, Ohtake T, et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008;88:7-15. doi: 10.1007/s12185-008-0120-5.
Gozzelino R, Arosio P. Iron homeostasis in health and disease. Int J Mol Sci 2016;17:E130. doi: 10.3390/ijms17010130.
Patel M, Ramavataram DV. Non transferrin bound iron: nature, manifestations and analytical approaches for estimation. Indian J Clin Biochem 2012;27:322-32. doi: 10.1007/s12291-012-0250-7.
Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomed Sci 2008;4:89-96.
Mahdi EA. Relationship between oxidative stress and antioxidant status in beta thalassemia major patients. Acta Chim Pharm Indica 2014;4:137-45.
Rujito L, Mulatsih S, Sofro ASM. Status of superoxide dismutase in transfusion dependent thalassaemia. N Am J Med Sci 2015;7:194-8. doi: 10.4103/1947-2714.157480.
Asif M, Manzoor Z, Farooq MS, et al. Status of oxidant, antioxidant and serum enzymes in thalassaemic children receiving multiple blood transfusions. J Pak Med Assoc 2015;65:838-43.
Lu JM, Lin PH, Yao Q, et al. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med 2010;14:840-60. doi: 10.1111/j.1582-4934.2009. 00897.x
Maskoen AM, Rahayu NS, Reniarti L, et al. Mutation spectrum of β-globin gene in thalassemia patients at Hasan Sadikin Hospital - West Java Indonesia. Cell Mol Biol (Noisy-le-grand) 2017;63:22-4. doi: 10.14715/cmb/2017.63. 12.6.
Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2012;2:a011734.
Jones E, Pasricha SR, Allen A, et al. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and â-thalassemia trait. Blood 2015; 125:873-80. doi: 10.1182/blood-2014-10-606491.
Wahidiyat PA, Gatot D, Tjitrasari T, et al. Phenotypic diversity in beta-HbE thalassemia patients. Pediatr Indones 2006;46:82-6. doi: 10.14238/pi46.2.2006.82-6.
Sripichai O, Makarasara W, Munkongdee T, et al. A scoring system for the classification of β-thalassemia/Hb E disease severity. Am J Hematol 2008;83:482-4. doi: 10.1002/ajh.21130.
Aphinives C, Kukongviriyapan U, Jetsrisuparb A, et al. Impaired endothelial function in pediatric hemoglobin E/β-thalassemia patients with iron overload. Southeast Asian J Trop Med Public Health 2014;45:1454-63.
Yanpanitch OU, Hatairaktham S, Charoensakdi R, et al. Treatment of â-thalassemia/hemoglobin E with antioxidant cocktails results in decreased oxidative stress, increased hemoglobin concentration, and improvement of the hypercoagulable state. Oxid Med Cell Longev 2015;2015. Article ID 537954, 8 pages. doi: 10.1155/2015/537954.
Fernandes MS, Rissi TT, Zuravski L, et al. Oxidative stress and labile plasmatic iron in anemic patients following blood therapy. World J Exp Med 2014;4:38-45. doi: 10.5493/wjem.v4.i3.38.
Abdalla MY, Fawzi M, Al-Maloul SR, et al. Increased oxidative stress and iron overload in Jordanian β-thalassemic children. Hemoglobin 2011;35:67-79. doi: 10.3109/03630269.2010. 544624.
Dhawan V, Kumar KR, Marwaha RK, et al. Antioxidant status in children with homozygous thalassemia. Indian Pediatr 2005;42:1141-5.